Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka Holdings’ Pharmaceutical Sales Top 1 Trillion Yen for First Time
May 15, 2014
- Hisamitsu Takes Aim at 190 Billion Yen Sales in FY2018
May 15, 2014
- Ono to Introduce Sales Reps Specializing in Oncology for Entry to Oncology Market in Japan
May 15, 2014
- Zeria Appoints New President for First Time in 32 Years
May 14, 2014
- Meiji Seika Pharma Pres. Matsuo to Helm Holding Firm
May 14, 2014
- Eisai Sales Up 4.7% Thanks to Humira, Halaven Growth
May 14, 2014
- Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
- 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
- Astellas FY2013 Sales Up 16% on Rosy Revenues from Xtandi, Betanis
May 13, 2014
- March Ethical Drug Sales Zoom 13.8% on Pre-Tax Hike Demand: Crecon Report
May 13, 2014
- Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
- Questionnaire Survey of Chronic Myeloid Leukemia Patients Finds 30 Unreported ADRs: Novartis
May 13, 2014
- Nippon Kayaku Predicts Remicade Biosimilar Sales of 1.1 Billion Yen for FY2014
May 13, 2014
- MTPC Plans to Reduce Costs by 10 Billion Yen by FY2016
May 12, 2014
- FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
- Shionogi Makes Record Operating, Ordinary Profits
May 12, 2014
- LEO Pharma Takes Over Marketing Authorization to Dovonex
May 12, 2014
- Eisai to Develop Novel Inflammatory Bowel Disease Treatment with University of Tsukuba
May 12, 2014
- Kissei Aims to Maintain Non-Consolidated Sales, Launch Hyperphosphatemia Treatment: New Midterm Plan
May 12, 2014
- DSP to Execute Option Rights to Codevelop Cerebral Infarction Cell Therapy in April-Sept.
May 9, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…